On Friday, 21 November 2025, the official starting signal was given in Berlin for STUDIEN WIRKEN, a broad-based initiative of the FUNKE Media Group that aims to make clinical trials in Germany more visible, impart knowledge and strengthen trust.
The initiative pursues an ambitious goal: to raise public awareness of clinical trials. After all, clinical trials are essential for developing innovative therapies, improving care and enabling patients to truly participate in medical progress. With strong partners from research, industry, patient organisations and politics, STUDIEN WIRKEN has created a unique alliance for this purpose.
As a scientific partner, NUM also provided important impetus on the podium at the kick-off: Dr Ramsia Geisler represented NUM on the panel "From midfield to the Champions League - how can Germany get back to the top of clinical research?" and contributed the perspectives of the NUM Study Network (NUM SN), which she heads as Managing Director. The NUM SN is a specialised Reseach Infrastructure within the NUM with the aim of optimising processes, networking stakeholders and thus accelerating clinical and clinical-epidemiological research in Germany. Prof Dr Janne J. Vehreschild, project manager of the NUM SN, is therefore a member of the STUDIEN WIRKEN Advisory Board.
Parallel to the kick-off, FUNKE is launching a comprehensive cross-media awareness campaign in print, digital and social media. An accompanying landing page provides background information, facts and an interactive study finder to help patients find their way around: